key: cord-1016042-hhhmkpd0
authors: Igawa, Gene; Yamamoto, Takamasa; Baba, Yuuna; Shinozuka, Konomi; Yuri, Maiko; Wakita, Mitsuru; Misawa, Shigeki; Miida, Takashi; Ai, Tomohiko; Tabe, Yoko
title: Clinical Evaluation of Siemens SARS-CoV-2 Total Antibody assay and IgG assay using the Dimension EXL 200 in the Tokyo Metropolitan area
date: 2021-11-16
journal: Heliyon
DOI: 10.1016/j.heliyon.2021.e08393
sha: 385ac8a6d7981b7c160429248a1f1f8105489d2c
doc_id: 1016042
cord_uid: hhhmkpd0

BACKGROUND: We evaluated the efficacy of the Siemens SARS-CoV-2 Total Antibody assay (CV2T) and IgG assay (CV2G) that can detect antibodies against the receptor binding domain of S antigen in patients with COVID-19 in a Tokyo metropolitan area. METHODS: Sensitivity and antibody levels were examined by CV2T and CV2G on Dimension EXL 200 using 236 serum samples obtained from 79 RT-PCR confirmed COVID-19 patients at multiple time points and were compared with disease severity by the World Health Organization criteria. The assay specificity was evaluated using samples collected before the COVID-19 pandemic. RESULTS: The sensitivity of CV2T and CV2G were low (16.7-21.4%) in days 0-6 and increased to 43.8-52.5% in days 7-13 and to 80.8-90.0% in days 14-20. The seroprevalences persisted after day 21 to days past 42 regardless of disease severity. In every day grouping, mean antibody levels were higher in severe cases than in mild cases with a significant difference in days 14-20 and days 20-27. The specificity was 97.9 % (95% CI; 92.8-99.8) for CV2T and 99.0 % (95% CI; 94.6-100) for CV2G. CONCLUSIONS: Our results indicate a high specificity and high sensitivity at 14 days of CV2T and CV2G as antibody detection assays.

A serious respiratory illness caused by the severe acute respiratory syndrome 46 coronavirus 2 (SARS-CoV-2), referred to as Coronavirus disease 2019 (COVID- 19) , 47

Fluorescence signal intensities measured at a wavelength of 612 nm were directly 110 correlated with antibody concentrations, which were indicated as antibody levels 111 (QUAL). For semiquantitative CV2G assay, Ind is used instead of QUAL. One QUAL 112 equal to one Ind. The limit of detection (LoD) for CV2G is 600 Ind, and assay linear 113 range is between 600 and 140,000 Ind. However, CV2T is a qualitative assay, and the 114 linear range and LoD have not been determined. Antibody levels greater than or equal to 115 1000 QAUL and 1000 Ind units were interpreted as positive (13). According to the 116 manufacture, 1000 QUAL equals to 12 BAU/ml for CV2T and 1000 Ind equals to 17 117 BAU/ml for CV2G. 118 119 2.3. Statistical analysis 120 RT-PCR was considered the gold standard for the detection of SARS-CoV-2, 121 and the sensitivity for the assays was assessed using days from the onset of symptoms. 122

Confidence intervals (CI) were calculated by the Clopper-Pearson method for 123 sensitivity and specificity. Antibody levels between Group M and Group S were 124 compared with Mann-Whitney U testing. Antibody levels between groups of days from 125 onset of symptoms were compared by Kruskal-Wallis analysis. A two-tailed p value of 126 <0.05 was considered statistically significant. Statistical analysis was performed by 127 EZR (14) . 128

The precision of the antibody assay was evaluated according to the Clinical 131 and Laboratory Standards Institute guideline EP15-A3 using QC materials consisting of 132 positive and negative serum controls for the antibodies against S1-RBD provided by the 133 manufacturer (Siemens Healthcare Diagnostics, Delaware, USA) and one pooled 134 sample obtained from patients with COVID-19 at Juntendo University Hospital. 135

Reproducibility (n = 20) was assessed by replicates in one day on one instrument. 136

Confidence of variation (CV) was 2.2-7.0 % for CV2T and 1.3-3.8 % for CV2G. 137

Within-laboratory reproducibility (n = 20) was assessed by duplicate assays two times a 138 day for five days. The CV was 4.0-5.7 % for CV2T and 2.9-7.5 % for CV2G. Next, sensitivity of the antibody assay was examined using a total of 236 151 samples obtained from 79 patients whose RT-PCR tests were positive for SARS-CoV-2. 152 Table 2 summarizes the seroprevalences measured in various timing from onset of 153 symptoms. The sensitivity increased relative to the day from onset of symptoms. The 154 seroprevalences measured by CV2T were relatively low (16.7-52.5%) in early phase 155 To determine dynamic changes of antibodies in the same patients, antibody 170 levels of the seroconverted patients who had more than three consecutive samples were 171 plotted as a function of days from onset of symptoms. Figure 2 shows that antibody 172 levels measured by either CV2T or CV2G increased in the early phase of the infection 173 and gradually decreased but remained positive in our observation period in both groups 174 onset of symptoms, Kruskal-Wallis analysis was performed, and a significant difference 176 was observed among the days from the onset of symptoms (p < 0.001). Post hoc 177 analysis using Steel-Dwass analysis demonstrated a significant difference in mean 178 antibody levels in days 0-6 when compared to later days. There was also a significant 179 difference in mean antibody levels in groups of day 7-13 when compared to other days. 180

However, no significant difference was observed in mean antibody levels in groups later 181 than days 14-20. 182 performance declared by the vendor before using EUA products. Thus, we first 199 validated the assay precision. According to the package insert, the CVs were set to be 200 under 10% and under 12% for repeatability and within-laboratory reproducibility, 201 respectively. Our results were lower than this and confirmed the manufacturer's claims. 202

In the determination of seroprevalences, most patients were seropositive at 203 days 14-20 and seropositivity persisted till days 42 plus. Similar to the previous studies, 204 one immunocompromised patient failed to seroconvert (19, 20) . This may indicate that 205 detectable amounts of antibodies cannot be produced in immunocompromised patients. 206

The sensitivity after 14 days from onset of symptoms in our study nearly 207 matched the package insert (CV2T: 100% and CV2G: 100%) (13). However, the 208 sensitivity reported by the manufacturer was higher in days 0-6 (CV2T: 66.67%; 209 CV2G: 61.9%) and days 7-13 (CV2T: 91.30%; CV2G: 92.3%) compared to our results. 210

A study using the Dimension Vista that shares the same technologies with Dimension 211 EXL 200 in the U.S. reported a sensitivity of 78% by CV2T after 14 days from onset of 212 symptoms, which that is lower than our study (18). This inconsistency might occur due 213 to the locality or the character diversity of the sample such as ethnicity, age, gender, and 214 underlying diseases.

reviewing the patients' charts, we did not find evidence of previous exposure to SARS 220 or MERS, which are quite rare disease in Japan. Using the pre-COVID-19 samples in 221 the specificity assay, our study showed high specificity in both CV2T (97.9%) and 222 CV2G (99.0%), which is essential for detecting antibodies. However, our specificity 223 results were lower than the Zilla et al. study which had high (100%) specificity using 224 184 samples in the total antibody assay using the Siemens Vista (18). The manufacturer 225 also claims 99.86% specificity for CV2T and 100% specificity for CV2G using 1529 226 and 1509 healthy samples collected before COVID-19 pandemic, respectively. 227

Although these discordances may be due to difference in samples, the difference may be 228

Comparing Group M and Group S, the antibody levels were significantly 230 higher in Group S in the second and third weeks. These results are similar to a study by 231

Long et al., which compared severe and non-severe groups from three hospitals in 232 China although significant difference was obtained only in days 8- 14 (23) . Several 233 studies also demonstrated positive correlations between disease severity and antibody 234 levels (9,17,24,25) while others did not (20,26). These contradicting results may have 235 occurred due to difference in sample size, the target for antibody detection (S protein or 236 N protein or S1-RBD), or the genetic diversity of patients. 237

The results of CV2T and CV2G are not comparable because the CV2G is 238 semi-quantitative assay, and the CV2T is qualitative assay. In our study, the CV2G 239 assay seems to yield higher antibody levels than the CV2T assay in both Group S and 240 Group M. However, further investigation was not able to perform because of the lack of 241 reference material. 242

The CDC recommend serology testing for suspectable COVID-19 patients In conclusion, the Siemens CV2T and CV2G could detect the S1-RBD 276 specific antibodies against SARS-CoV-2 at approximately 14 days after onset with a 277 high sensitivity. Though current use of this assay as a screening tool is limited as 278 

Current methods for 292 diagnosis of human coronaviruses: pros and cons

Nucleic Acid Testing Results for Severe Acute Respiratory Syndrome 296

Coronavirus 2 from Thermal Inactivation of Samples with Low Viral Loads

Discrimination of False COVID-19

Review of Current Advances in Serologic Testing for COVID-19

Diagnostics for SARS-CoV-2 detection: A 309 comprehensive review of the FDA-EUA COVID-19 testing landscape

COVID-19 Serology Surveillance Strategy

Covid-19 vaccine frontrunners 316 and their nanotechnology design

Defining the features and duration of antibody responses to SARS-CoV-2 319 infection associated with disease severity and outcome. Sci Immunol

Rapid Generation of Neutralizing Antibody Responses

Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-332 binding domain IgG correlate with virus neutralization

EUA Authorized Serology Test Performance

Investigation of the freely available easy-to-use software "EZR" for 339 medical statistics

Clinical 341 validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) 342 reveals improved sensitivity and a good correlation with virus neutralization 343 titers

Evaluation of 345 three fully-automated SARS-CoV-2 antibody assays

CoV-2 IgG or total antibody

Variable 352 Performance in 6 Commercial SARS-CoV-2 Antibody Assays

Convalescent Plasma and Seroprevalence Screening

SARS-CoV-2 infection in 356 immunocompromised patients: humoral versus cell-mediated immunity

SARS-CoV-2 antibody responses do not predict COVID-19 disease severity

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody 364 23

Serum IgA, IgM, and IgG 374 responses in COVID-19

Clinical and 376 immunological assessment of asymptomatic SARS-CoV-2 infections

Multi-center nationwide comparison of seven serology assays reveals a SARS

CoV-2 non-responding seronegative subpopulation

Interim Guidelines for COVID-19 Antibody Testing